Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 11/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26249773 | 0.91 | LMNA (0.35) | ADRB2ADRB1LTB4RLTB4R2PLA2G2C | |
| SCHEMBL26252975 | 0.88 | ADRB2 (0.38) | ADRB2ADRB1LTB4RLTB4R2HDAC1 | |
| SCHEMBL26253714 | 0.86 | ADRB2 (0.36) | ADRB2ADRB1LTB4RLTB4R2HDAC1 | |
| SCHEMBL26253853 | 0.85 | PLA2G2C (0.34) | MPOPLA2G2C | |
| SCHEMBL26254335 | 0.85 | MPO (0.38) | ADRB2ADRB1LTB4RLTB4R2HDAC1 | |
| SCHEMBL23833101 | 0.84 | LTB4R (0.39) | ADRB2ADRB1LTB4RLTB4R2HDAC1 | |
| SCHEMBL22526813 | 0.84 | LTB4R (0.39) | ADRB2ADRB1LTB4RLTB4R2HDAC1 | |
| SCHEMBL26253731 | 0.84 | PLA2G2C (0.33) | MPOPLA2G2C | |
| SCHEMBL23833146 | 0.83 | AAK1 (0.39) | ADRB2ADRB1HDAC1HDAC6PPARG | |
| SCHEMBL23833150 | 0.83 | AAK1 (0.39) | ADRB2ADRB1HDAC1HDAC6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | ADRB2 4571/4885ADRB1 4560/4885LTB4R 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.